Drugs / Bemnifosbuvir/Ruzasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07314346 | Jan 2025 → Aug 2026 overdue | — | Atea Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus ateapharma.com ↗
BEM/RZR demonstrated statistical non-inferiority compared to the fixed-dose combination of sofosbuvir and velpatasvir (SOF/VEL) in the modified intent-to-treat (mITT) population, achieving the trial’s primary endpoint. |
| 2026-05-27 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 ateapharma.com ↗
today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. |
| 2026-05-13 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline ateapharma.com ↗
Proton-pump inhibitor omeprazole did not affect the plasma pharmacokinetics of bemnifosbuvir and ruzasvir fixed-dose combination in healthy participants |
| 2025-11-12 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update ateapharma.com ↗
New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV |
| 2025-11-07 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 ateapharma.com ↗
These modeling data will be presented at The Liver Meeting ® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 7-11 in Washington, DC. |
| 2025-05-07 | Atea Pharmaceuticals, Inc. | Results Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 ateapharma.com ↗
With a short 8-week treatment duration, the Phase 2 results showed a robust 98% (210/215) sustained virologic response rate at 12 weeks post-treatment (SVR12) with the regimen in the “Per-Protocol Treatment-Adherent Population.” |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemnifosbuvir/Ruzasvir | “Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone” NCT07314346 ↗ |
| Known as | BEM/RZR | “Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone” NCT07314346 ↗ |
| Route | Oral | “Multiple Oral Doses of BEM/RZR FDC” NCT07314346 ↗ |